• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
July 27, 2020

Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

Read More
June 18, 2020

2020 Annual General Meeting – all Resolutions Passed

Read More
June 16, 2020

Total Share Capital Notification

Read More
June 11, 2020

ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding

Read More
June 11, 2020

Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline

Read More
June 05, 2020

Notification of Change of Registered Office Address

Read More
June 02, 2020

Notification of Change of AGM Venue

Read More
May 21, 2020

Notice of AGM and posting of Report & Accounts

Read More
May 18, 2020

TR1 – Notification of major interest in shares by Lanstead Capital

Read More
May 14, 2020

ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka

Read More
April 30, 2020

Audited Report & Accounts published on website

Read More
April 30, 2020

FINAL RESULTS For the 12 months ended 31 December 2019

Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy